↓ Skip to main content

Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

Overview of attention for article published in Journal for Immunotherapy of Cancer, April 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news
1 news outlet
blogs
2 blogs
twitter
8 X users
patent
1 patent

Citations

dimensions_citation
162 Dimensions

Readers on

mendeley
117 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
Published in
Journal for Immunotherapy of Cancer, April 2015
DOI 10.1186/s40425-015-0055-3
Pubmed ID
Authors

Asim Amin, Arkadiusz Z Dudek, Theodore F Logan, Raymond S Lance, Jeffrey M Holzbeierlein, Jennifer J Knox, Viraj A Master, Sumanta K Pal, Wilson H Miller, Lawrence I Karsh, Irina Y Tcherepanova, Mark A DeBenedette, W Lee Williams, Douglas C Plessinger, Charles A Nicolette, Robert A Figlin

Abstract

AGS-003 is an autologous immunotherapy prepared from fully matured and optimized monocyte-derived dendritic cells, which are co-electroporated with amplified tumor RNA plus synthetic CD40L RNA. AGS-003 was evaluated in combination with sunitinib in an open label phase 2 study in intermediate and poor risk, treatment naïve patients with metastatic clear cell renal cell carcinoma (mRCC). Twenty-one intermediate and poor risk patients were treated continuously with sunitinib (4 weeks on, 2 weeks off per 6 week cycle). After completion of the first cycle of sunitinib, patients were treated with AGS-003 every 3 weeks for 5 doses, then every 12 weeks until progression or end of study. The primary endpoint was to determine the complete response rate. Secondary endpoints included clinical benefit, safety, progression free survival (PFS) and overall survival (OS). Immunologic response was also monitored. Thirteen patients (62%) experienced clinical benefit (9 partial responses, 4 with stable disease); however there were no complete responses in this group of intermediate and poor risk mRCC patients and enrollment was terminated early. Median PFS from registration was 11.2 months (95% CI 6.0, 19.4) and the median OS from registration was 30.2 months (95% CI 9.4, 57.1) for all patients. Seven (33%) patients survived for at least 4.5 years, while five (24%) survived for more than 5 years, including 2 patients who remain progression-free with durable responses for more than 5 years at the time of this report. AGS-003 was well tolerated with only mild injection-site reactions. The most common adverse events were related to expected toxicity from sunitinib therapy. In patients who had sequential samples available for immune monitoring, the magnitude of the increase in the absolute number of CD8(+) CD28(+) CD45RA(-) effector/memory T cells (CTLs) after 5 doses of AGS-003 relative to baseline, correlated with overall survival. AGS-003 in combination with sunitinib was well tolerated and yielded supportive immunologic responses coupled with extension of median and long-term survival in an unselected, intermediate and poor risk prognosis mRCC population. #NCT00678119.

X Demographics

X Demographics

The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 117 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 <1%
Russia 1 <1%
Germany 1 <1%
Switzerland 1 <1%
Unknown 113 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 22 19%
Researcher 19 16%
Student > Master 17 15%
Student > Bachelor 8 7%
Student > Doctoral Student 8 7%
Other 16 14%
Unknown 27 23%
Readers by discipline Count As %
Medicine and Dentistry 25 21%
Biochemistry, Genetics and Molecular Biology 15 13%
Agricultural and Biological Sciences 14 12%
Immunology and Microbiology 14 12%
Pharmacology, Toxicology and Pharmaceutical Science 7 6%
Other 10 9%
Unknown 32 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 June 2022.
All research outputs
#1,417,713
of 25,371,288 outputs
Outputs from Journal for Immunotherapy of Cancer
#355
of 3,421 outputs
Outputs of similar age
#17,552
of 279,751 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 15 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,421 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,751 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.